
News|Articles|July 30, 2025
Could targeting retinal non-perfusion be the key to achieving true disease modification in diabetic retinopathy?
Advertisement
Sponsored Supplement:
The triad of inflammation, neuropathy, and vasculopathy plays a key role in the development and progression of diabetic retinopathy (DR).1 Dr. Varun Chaudhary and Dr. Patrick Bussfeld, discuss how retinal non-perfusion (RNP) specifically drives disease progression and why it should be explored as a treatment target.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA update: Outlook Therapeutics receives CRL for resubmitted ONS-5010 BLA
2
Innovations in glaucoma poised for breakthrough in 2026 (and what might hold them back)
3
FDA approvals in 2025: What changed and why it matters for ophthalmologists
4
PRIMAvera study: Central vision improvement with subretinal implant
5












































